A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
Davendra Sohal, Smitha Krishnamurthi, Rita Tohmé, Xiaorong Gu, Daniel J. Lindner, Terry H. Landowski, John J. Pink, Tomas Radivoyevitch, Sherry Fada, Zhenghong Lee, Dale R. Shepard, Alok A. Khorana, Yogen Saunthararajah
Abstract
resectable PDAC. We concluded that CDA activity is increased not just locally but also systemically in metastatic PDAC, suggesting a need for even higher CDA-inhibitor doses than used here.
Topics & Concepts
DecitabineMedicineGemcitabineCytidine deaminaseNeutropeniaInternal medicineOncologyAzacitidineGastroenterologyCancer researchCancerPharmacologyChemotherapyImmunologyDNA methylationChemistryGene expressionGeneAntibodyBiochemistryPancreatic and Hepatic Oncology ResearchEpigenetics and DNA MethylationPancreatitis Pathology and Treatment